Kyorin Pharmaceutical Co., Ltd.
https://www.kyorin-pharm.co.jp/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kyorin Pharmaceutical Co., Ltd.
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Deal Watch: Deal Volume On The Rise Heading Into J.P. Morgan
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
Scorpion Nabs $108m, Biopharma Veterans For Precision Oncology 2.0
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Probi Targets US Expansion With Vital Nutrients Investment
European Probiotics specialist Probi has acquired a stake in US supplements firm Vital Nutrients, in a deal which will see the companies collaborate on new product development.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- ActivX Biosciences, Inc., KYORIN Holdings, Inc., Kyorin Rimedio